BACTIGUARD Aktie

 

The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Tuesday 19 May 2026 in Stockholm, has been appointed. The Nomination Committee will consist of: · Helena Borglund (appointed by TomBact AB) · Malin af Petersens (appointed by GIDL Invest AB) · Jan Ståhlberg (appointed by Jan Ståhlberg) · Mats J Andersson (appointed by Nordea Fonder) · Jannis Kitsakis (appointed by Fjärde AP Fonden) In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of...

Continued profitability and clinical evidence supporting future growth Third quarter 2025 (July – September) · Total revenue amounted to SEK 48.4 (73.9) million, a decrease of SEK 25.5 million corresponding to 34.5%. · Net sales amounted to SEK 45.5 (67.3) million, a decrease of SEK 21.9 million corresponding to 32.5%. Adjusted for currency effects of SEK -3.4 million, net sales decreased by 27.4%. · Operating loss amounted to SEK 6.4 (1.9) million. · EBITDA amounted to SEK 5.3 (9.9) million. · Net loss for the period amounted to SEK 7.5 (4.7) million. · Loss per share,...

Bactiguard Holding AB (publ) publishes its interim report for the third quarter on Thursday 23 October 2025 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com (https://ir.bactiguard.com/report/q3-2025/). To participate in the audiocast, please use this link: ir.bactiguard.com/report/q3-2025/ To participate only by conference call, please register via the...

Two independent studies, recently published in leading medical journals, add to the growing clinical evidence on Bactiguard-coated orthopedic trauma products available in the United Kingdom and across Europe. Conducted by trauma surgeons and surgical teams, the studies highlight the strong interest in safe and effective solutions to prevent implant-associated infections in orthopedic trauma procedures. One of the studies, published late September, is the first clinical comparative evaluation of noble metal alloy-coated nails in a high-risk orthopaedic trauma population. The study was carried...

NL0015001BF4 NL0015001OI1 NO0005806802 NO0006390301 NO0010015175 NO0010098247 NO0010257728 NO0010360266 NO0010692130 NO0010713936 NO0010892359 NO0010894231 NO0010963275 NO0011002651 NO0012697715 NO0013119255 NO0013186460 NO0013461350 NZFAPE0001S2 NZGNEE0001S7 SE0000106205 SE0000107203 SE0000112252 SE0000171886 SE0000188518 SE0000195810 SE0000233934 SE0000648669 SE0000671745 SE0000683484 SE0000949331 SE0001057910 SE0001075102 SE0001161654 SE0001552357 SE0001860511 SE0001863291 SE0002110064 SE0002148817 SE0002190926 SE0002485979 SE0003273531 SE0003756758 SE0003815604 SE0003917798 SE0003943620 SE0004210854 SE0004898799 SE0005101003 SE0005162880 SE0005250719 SE0005308558 SE0005392537 SE0005454873 SE0005624756 SE0005768124 SE0005794617 SE0005878741 SE0005881786 SE0005933082 SE0005999836 SE0006091997 SE0006261046 SE0006343745 SE0006421871 SE0006510335 SE0007045414 SE0007074166 SE0007075247 SE0007100359 SE0007158118 SE0007413455 SE0007438577...

Positive EBITDA momentum carried forward in Q2 Second quarter 2025 (April – June) · Total revenue amounted to SEK 52.1 (60.9) million, a decrease of SEK 8.8 million corresponding to 14.4%. · Net sales amounted to SEK 48.2 (57.4) million, a decrease of SEK 9.1 million corresponding to 15.9%. Adjusted for currency effects of SEK -3.8 million, net sales decreased by 9.4%. · Operating loss amounted to SEK 7.3 (10.8) million. · EBITDA amounted to SEK 4.4 (1.2) million. · Net loss for the period amounted to SEK 8.1 (14.3) million. · Loss per share, before and after dilution,...

Bactiguard Holding AB (publ) publishes its interim report for the second quarter on Tuesday 15 July 2025 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com. (https://ir.bactiguard.com/report/q2-2025/) To participate in the audiocast, please use this link: ir.bactiguard.com/report/q2-2025/ To participate only by conference call, please register via the link...

At Bactiguard Holding AB's (publ) Annual General Meeting (AGM) on 15 May 2025, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2024 and decided that no dividend for the financial year 2024 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board of Directors and CEOs were discharged from liability for their administration of the company for the financial year 2024. The AGM resolved that the remuneration until the next AGM shall be paid in an amount of SEK 750,000 to the Chairman of the...

Continued profitability and revenue growth for Bactiguard First quarter 2025 (January – March) · Total revenue amounted to SEK 62.7 (58.8) million, an increase of SEK 3.9 million corresponding to 6.7%. · Net sales amounted to SEK 59.1 (53.9) million, an increase of SEK 5.1 million corresponding to 9.5%. Adjusted for currency effects of SEK 1.7 million, net sales increased by 6.3%. · Operating loss amounted to SEK 2.6 (12.9) million. · EBITDA amounted to SEK 9.4 (-1.5) million. · Net loss for the period amounted to SEK 4.7 (9.9) million. · Loss per share, before and after...

The Annual and Sustainably Report 2024 for Bactiguard Holding AB (publ) is now available at ir.bactiguard.com/ In 2024, Bactiguard completed the strategic shift needed to enable the company to be the premier choice for both current and future partners. This transformation delivered positive financial results and positioned Bactiguard for growth. The company achieved EBITDA profitability, which was a core commitment to its shareholders, along with positive cash flow from operating activities. Reaching these milestones marks a significant achievement, allowing Bactiguard to further develop its...

Bactiguard Holding AB (publ) publishes its interim report for the first quarter on Thursday 24 April 2025 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com (https://ir.bactiguard.com/report/q1-2025/). To participate in the audiocast, please use this link: ir.bactiguard.com/report/q1-2025/ To participate only by conference call, please register via the...

The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting (AGM) to be held on Thursday, 15 May 2025 at 9 am at Posthuset 7A, Vasagatan 28 in Stockholm. Registration will commence at 8 am. Right to participate and notice of intent to participate Shareholders wishing to participate in the Annual General Meeting must: · be recorded in the share register maintained by Euroclear Sweden AB (“Euroclear”) on Wednesday 7 May 2025 (“the record date”) · provide notice to the company of their...

The Nomination Committee of Bactiguard Holding AB (the "Company") today informs about the proposal regarding the composition of the Board of Directors for the Annual General Meeting on 15 May 2025. The Nomination Committee proposes re-election of Thomas von Koch, Dr Richard Kuntz, Professor Anna Martling, Magdalena Persson and Jan Ståhlberg as Board Members. Thomas von Koch is proposed to be re-elected as the Chairman of the Board of Directors. The Nomination Committee's other proposals will be made public in the notice convening the Annual General Meeting to be held on 15 May 2025....

Bactiguard Holding AB (publ.) today announces its updated strategic and financial targets following a review announced in connection with the 2024 Q3 report. The updated targets reflect a sharpened strategic focus on the license business and EBITDA profitability, a transformation delivered in 2024. The updated strategic and financial targets will be presented at an audiocast tomorrow 6 March at 10:00 CET. Bactiguard has conducted a comprehensive analysis of the market potential and partnership opportunities for its infection prevention technology. This includes an in-depth evaluation of key...

Bactiguard Holding AB (publ) publishes its year-end report for 2024 on Thursday 6 February 2025 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com. To participate in the audiocast, please use this link: ir.bactiguard.com/report/q4-2024/ To participate only by conference call, please register via the link above. Questions can be asked either in writing via...